2470424-39-4
2470424-39-4
Chemical Structure
SGC-CK2-1
- CAS No.: 2470424-39-4
- Formula:C20H21N7O
- Molecular Weight:375.43
IUPAC Name: N-(5-((3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl)amino)-2-methylphenyl)propionamide
InChIKey: YKDZIFFKQUNVHH-UHFFFAOYSA-N
SMILES: CCC(NC1=CC(NC2=NC3=C(C#N)C=NN3C(NC4CC4)=C2)=CC=C1C)=O
Biological Activity: SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SGC-CK2-1 | 99.87% | SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.74
HY-12570CK2-IN-9 -
Similarity Score 0.63
HY-163783CSNK2-IN-1 -
Similarity Score 0.57
HY-148763CK2-IN-6 -
Similarity Score 0.52
HY-117203ACDK12-IN-E9 -
Similarity Score 0.48
HY-103712ASamuraciclib hydrochloride -
Similarity Score 0.48
HY-103712Samuraciclib -
Similarity Score 0.48
HY-159827Cenacitinib -
Similarity Score 0.47
HY-115729PROTAC CDK9 ligand-1 -
Similarity Score 0.47
HY-115729A(R)-PROTAC CDK9 ligand-1 -
Explore the MedChemAI to find more analogs
References
- [1]. Carrow I Wells, et al. Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Cell Chem Biol. 2021 Apr 15;28(4):546-558.e10. [Content Brief]
- [2]. Marco P Licciardello, et al. A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. Trends Pharmacol Sci. 2021 May;42(5):313-315. [Content Brief]
